Clinical Trial Update: Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase [Phase 2]

View source ↗

Summary

Phase 2 extension study assessing the safety and tolerability of sustained-release fesoterodine (SP668) in subjects with overactive bladder, following a double-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Fesoterodine (fesoterodine)

Snippet

Sponsor: Pfizer | Conditions: Overactive Bladder | Phase 2 | Status: COMPLETED